#amyloidosisJC Transcript
Healthcare social media transcript of the #amyloidosisJC hashtag.
– ().
See #amyloidosisJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Suresh Balasubramanian @malignantheme Please join us for the last journal club session of "Untangling Amyloidosis 2019" before the ASH. 👉 "MRD in amyloidosis" tonight @9PM. https://t.co/8q0fEeTM6y. ✊🏼Moderators: @holly_dlduwls, me & @NB191186. 🙏🏽#amyloidosisjc @Amyloid_Planet |
 | Dr. Jeffrey Zonder @Amyloid_Planet RT @malignantheme: Please join us for the last journal club session of "Untangling Amyloidosis 2019" before the ASH. 👉 "MRD in amyloidosis" tonight @9PM. https://t.co/8q0fEeTM6y. ✊🏼Moderators: @holly_dlduwls, me & @NB191186. 🙏🏽#amyloidosisjc @Amyloid_Planet |
| Dr. Jeffrey Zonder @Amyloid_Planet Join us for #amyloidosisjc this evening at 9 pm EST. We’ll be discussing if/when/how to use MRD testing for AL #amyloidosis. For a brief synopsis of the paper: https://t.co/pMFVa5dPaC @malignantheme @NB191186 @holly_dlduwls @Amyloidosisfdn @AmyloidosisSupp @Amyloidosis_ARC |
 | Raj Chakraborty @rajshekharucms RT @Amyloid_Planet: Join us for #amyloidosisjc this evening at 9 pm EST. We’ll be discussing if/when/how to use MRD testing for AL #amyloidosis. For a brief synopsis of the paper: https://t.co/pMFVa5dPaC @malignantheme @NB191186 @holly_dlduwls @Amyloidosisfdn @AmyloidosisSupp @Amyloidosis_ARC |
 | Holly Lee @hollyleeYJ RT @Amyloid_Planet: Join us for #amyloidosisjc this evening at 9 pm EST. We’ll be discussing if/when/how to use MRD testing for AL #amyloidosis. For a brief synopsis of the paper: https://t.co/pMFVa5dPaC @malignantheme @NB191186 @holly_dlduwls @Amyloidosisfdn @AmyloidosisSupp @Amyloidosis_ARC |
| Suresh Balasubramanian @malignantheme 1 more hour to go for the last journal club session of "Untangling Amyloidosis 2019" before the ASH. 👉 "MRD in amyloidosis" @9PM. https://t.co/8q0fEfbmY6. ✊🏼Moderators: @holly_dlduwls, me & @NB191186. 🙏🏽#amyloidosisjc @Amyloid_Planet |
| Holly Lee @hollyleeYJ Just 30 min until today's #AmyloidosisJC on "MRD in amyloidosis" @9pm - Join us! https://t.co/PIKsLAnvRt. ✊🏼Moderators: @malignantheme & @NB191186 & myself. 🙏🏽#Amyloidosisjc @Amyloid_Planet |
| Suresh Balasubramanian @malignantheme Good evening everyone!! Welcome aboard!! We will be discussing the role of "MRD in AL amyloidosis". For a detailed synopsis 👉🏽https://t.co/65eOTf0zYe #amyloidosisjc @holly_dlduwls @NB191186 https://t.co/oVQjQffMUn |
| Suresh Balasubramanian @malignantheme Please introduce yourself and relevant COI pertinent to the discussion tonight. Also please use the hashtag #amyloidosisJC for all your tweets here 🙏🏼 |
 | Andrew Kin @Karmanos_DrAKin Andrew Kin, Amyloid & Myeloma faculty at Karmanos with @Amyloid_Planet . No relevant COI. #amyloidosisjc |
| Holly Lee @hollyleeYJ Welcome to today's #AmyloidosisJC, a discussion on the role of MRD in AL amyloidosis based on this article👉https://t.co/PIKsLAnvRt. My name is Holly Lee, hematology fellow from University of Calgary, Canada. No COI |
| Suresh Balasubramanian @malignantheme I am Suresh Kumar Balasubramanian from Wayne State University/ Karmanos Cancer Institute. No COI to declare. #amyloidosisJC |
 | Vaishali Sanchorawala @vsanchorawala Vaishali Sanchorawala from @BU_Amyloidosis No COI #amyloidosisjc |
 | silva pregja @silvapregja @malignantheme @holly_dlduwls @NB191186 Good evening, Silva Pregja, Karmanos Cancer Institute, looking forward to tonight’s discussion #AmyloidosisJC |
 | Vijendra Singh @vijsinghmd Vijendra Singh @karmanoscancer Hematology fellow, No COI #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet Jeffrey Zonder, Multidisciplinary Team Leader for Multiple Myeloma and #amyloidosis @karmanoscancer in Detroit MI. my COI are listed @ https://t.co/THV0rpamMW hi everybody #amyloidosisjc |
| Holly Lee @hollyleeYJ #amyloidosisjc. Welcome to today's journal club, a discussion on the role of MRD in AL amyloidosis based on this article👉https://t.co/PIKsLAnvRt. My name is Holly Lee, hematology fellow from University of Calgary, Canada. No COI |
 | Andrew Staron @a_staron Andrew Staron, hematology fellow from @BUHemeOncFellow and @BU_Amyloidosis No COI. Keeping warm by my netflix fireplace and looking forward to the discussion tonight. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet RT @holly_dlduwls: #amyloidosisjc. Welcome to today's journal club, a discussion on the role of MRD in AL amyloidosis based on this article👉https://t.co/PIKsLAnvRt. My name is Holly Lee, hematology fellow from University of Calgary, Canada. No COI |
 | omar @omaralbanyan Omar Albanyan. Heme/onc fellow @karmanoscancer #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet RT @malignantheme: I am Suresh Kumar Balasubramanian from Wayne State University/ Karmanos Cancer Institute. No COI to declare. #amyloidosisJC |
| Suresh Balasubramanian @malignantheme Here is a visual abstract of tonight’s JC paper for a quick reference. ©️ ✋🏼 @holly_dlduwls #amyloidosisjc https://t.co/VlCJcWPOyQ |
 | Victor H Jimenez-Zepeda @vhugo8762 victor Jimenez Zepeda from TBCC, No COI #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet Nice summary of tonight's #amyloidosisjc article. |
 | Susan Bal @SusanBal9 #amyloidosisjc Hello Susan Bal from UAB. |
 | Ahmad Masri @MasriAhmadMD RT @malignantheme: Here is a visual abstract of tonight’s JC paper for a quick reference. ©️ ✋🏼 @holly_dlduwls #amyloidosisjc https://t.co/VlCJcWPOyQ |
| Andrew Staron @a_staron @NB191186 What are the 3 different modalities for assessing for MRD? #amyloidosisjc |
| Ahmad Masri @MasriAhmadMD Ahmad Masri Cardiologist No COI #amyloidosisjc |
| Suresh Balasubramanian @malignantheme There is a bit of lag in the tweets. Please refresh your screen now and then #amyloidosisjc |
| Holly Lee @hollyleeYJ Here is the link to the 2019 paper👉Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis by Muchtar et al. https://t.co/xoeNp6S58X. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @holly_dlduwls (or others) can u comment on relative sensitivity of different methods for assessing MRD status? #amyloidosisjc |
| Holly Lee @hollyleeYJ Design: retrospective observation study, Objective: assess the impact of undetectable clonal plasma cells at end of first line therapy (EOT) on overall survival of AL amyloidosis patients. #amyloidosisjc |
| Holly Lee @hollyleeYJ Inclusion: among the original 173 patients with newly diagnosed AL amyloidosis patients (from the previous 2017 study), 82 patients who had MFC based MRD testing at EOT were included in the current study (2019). #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet @holly_dlduwls @holly_dlduwls will be elaborating that in the next tweet #amyloidosisjc |
| Holly Lee @hollyleeYJ Link to the 2017 paper👉The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Muchtar E et al. https://t.co/cqYraWYRlu. #amyloidosisjc |
| Holly Lee @hollyleeYJ MRD assessment by MFC: single 7-color tube MFC analysis (sensitivity 1x10^-4 to 2x10^-5) with median gated events 489,922. #amyloidosisjc |
 | Ibrahim Azar, MD @ibrahimazaronc Ibrahim Azar, @karmanoscancer Hem/Onc fellow #amyloidosisjc |
| Andrew Staron @a_staron @Amyloid_Planet @holly_dlduwls ASO RQ-PCR = 10^-5; NGS = 10^-6; dPCR = 10^-5; MFC = 10^-4 or 10^-5; NGF = 10^-6. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala RT @a_staron: @Amyloid_Planet @holly_dlduwls ASO RQ-PCR = 10^-5; NGS = 10^-6; dPCR = 10^-5; MFC = 10^-4 or 10^-5; NGF = 10^-6. #amyloidosisjc |
| Andrew Staron @a_staron @Amyloid_Planet @holly_dlduwls These are different modalities tested in MM. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme RT @a_staron: @Amyloid_Planet @holly_dlduwls ASO RQ-PCR = 10^-5; NGS = 10^-6; dPCR = 10^-5; MFC = 10^-4 or 10^-5; NGF = 10^-6. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet RT @holly_dlduwls: Link to the 2017 paper👉The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Muchtar E et al. https://t.co/cqYraWYRlu. #amyloidosisjc |
| omar @omaralbanyan RT @a_staron: @Amyloid_Planet @holly_dlduwls ASO RQ-PCR = 10^-5; NGS = 10^-6; dPCR = 10^-5; MFC = 10^-4 or 10^-5; NGF = 10^-6. #amyloidosisjc |
| Ahmad Masri @MasriAhmadMD RT @a_staron: @Amyloid_Planet @holly_dlduwls ASO RQ-PCR = 10^-5; NGS = 10^-6; dPCR = 10^-5; MFC = 10^-4 or 10^-5; NGF = 10^-6. #amyloidosisjc |
 | Pedro Graziano Sanchez @wikimagen RT @malignantheme: Here is a visual abstract of tonight’s JC paper for a quick reference. ©️ ✋🏼 @holly_dlduwls #amyloidosisjc https://t.co/VlCJcWPOyQ |
| Holly Lee @hollyleeYJ Moving on to Results 👉 Result 1. Baseline patient characteristics (n=82):❗84% of patients had ASCT as 1st line therapy – selection bias❓primarily transplant eligible patients, generally fit and do not have extensive organ involvement. #amyloidosisjc https://t.co/d0S1jbjpnJ |
| Victor H Jimenez-Zepeda @vhugo8762 Vaishali is presenting at ASH this year their experience withNGS/clonoseq.https://t.co/LnQNhRHMaa NGS was successful at identifying the clone in 27 out of 37, thus, the method matters as the clone in AL amyloid is smaller. Also proper timing for assessment is key. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @a_staron @Amyloid_Planet @holly_dlduwls That was helpful! Definitely this will be pinned from tonight's JC #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet and no consensus re: optimal method in either #myeloma ar #amyloidosis #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @vhugo8762 We will present data in 10 patients post treatment with NGS. #amyloidosisjc |
| Holly Lee @hollyleeYJ Result 2: 29% (24) had MRD➖ and 71% (58) had MRD➕ at EOT. 19.5% (16) CR, 46.3% (38) VGPR, and 34.1% (28) <VGPR. Median time from diagnosis to EOT MFC was 6 months, longer for non-ASCT vs ASCT patients (median 11 vs 6 months, P = 0.002). #amyloidosisjc https://t.co/QsENHcSug6 |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet @a_staron NGF seems to be more reproducible and deep? It will be great if you can highlight the panel of genes that are tested in NGS #amyloidosisjc |
| Holly Lee @hollyleeYJ Result 3. Patient outcome (median 4.6 year follow up): MRD➖ was associated with improved PFS compared to MRD➕ (3-year PFS 88% vs. 28%, p<0.001). No difference in OS (3-year OS 96% vs. 84%, p=0.17). #amyloidosisjc https://t.co/vrHrh9SMrF |
| Vijendra Singh @vijsinghmd For NGS MRD testing here, do we need pt sample prior to treatment as we need them in ALL or other diseases @Amyloid_Planet #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @DrSinghvij @Amyloid_Planet Yes, absolutely. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @DrSinghvij @Amyloid_Planet That's the great question! atleast in myeloid neoplasms, yes! So as well here i believe. Is there a standard panel atleast in clinical trials? 🤔 #amyloidosisjc |
| Andrew Staron @a_staron @Amyloid_Planet IMWG put out consensus criteria for MRD in MM (https://t.co/air18M03Pf) which for flow includes processing technique guidelines and minimum sensitivity 10^-5. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @BU_Amyloidosis #amyloidosisjc |
| Vijendra Singh @vijsinghmd @malignantheme @Amyloid_Planet common sense says the ones which are mutated and not germ line should be used for MRD testing. Waiting from experts #amyloidosisjc |
| Holly Lee @hollyleeYJ Result 4. Subgroup analysis: Among patients with VGPR or CR, MRD➖ was associated with better PFS compared MRD➕ (3-year PFS 88% vs. 46%, p=0.003), particularly among patients who achieved CR (3-year PFS 100% vs. 33%, p=0.001). #amyloidosisjc https://t.co/3Kd3vozojr |
| Holly Lee @hollyleeYJ In contrast, difference in PFS advantage in VGPR MRD➖patients compared to VGPR MRD➕patients was not statistically significant (p=0.14). #amyloidosisjc |
| Andrew Staron @a_staron @malignantheme @Amyloid_Planet I believe typically IGH-VDJH, IGH-DJH, or IGK. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet RT @holly_dlduwls: Result 3. Patient outcome (median 4.6 year follow up): Result 3. Patient outcome (median 4.6 year follow up): MRD➖ was associated with improved PFS compared to MRD➕ (3-year PFS 88% vs. 28%, p<0.001). No difference in OS (3-year OS 96% vs. 84%, p=0.17). #amyloidosisjc https://t.co/vrHrh9SMrF |
| Victor H Jimenez-Zepeda @vhugo8762 The rate of CR seems to be lower of that expected for this population of patients mainly treated with autoSCT #amyloidosisjc |
| Andrew Staron @a_staron @NB191186 I believe so, good outcomes with next lines of therapy. #amyloidosisjc |
| Vijendra Singh @vijsinghmd A Layman question: What is so unique about these plasma cell disorders that even after MRD negativity we do not have cure ? @malignantheme #amyloidosisjc |
| Holly Lee @hollyleeYJ Result 5: MRD➖ compared with MRD➕ among deep responders was associated with lower level of iFLC (median 1.1 vs. 1.7mg/dL, p=0.02) and higher frequency of renal response (100% vs. 68%; p=0.005). #amyloidosisjc |
| Victor H Jimenez-Zepeda @vhugo8762 we are now debating the use of CR or dFLC<10 as predictors and/or therapy goals, correlation of the above and MRD status might also be interested to see #amyloidosisjc |
| Holly Lee @hollyleeYJ @vhugo8762 Also, interesting report by Muchtar et al. 2019, looked at the depth of response by nadir iFLC <2mg/d #amyloidosisjc. https://t.co/sHvPxX4S3k |
| Andrew Staron @a_staron @DrSinghvij @malignantheme Plasma cells can resist treatments and can be patchy, even our best techniques for MRD testing have their limitations. #amyloidosisjc |
| Vijendra Singh @vijsinghmd @SusanBal9 @malignantheme But that should be the case in other diseases as well. #amyloidosisjc @SusanBal9 |
| Holly Lee @hollyleeYJ When assessing independent organ response, this difference was not found in cardiac response. 20 patients available for cardiac response assessment, all patients with MRD➖ (n = 8) had cardiac response (100%), compared to 10/12 (83%) in MRD➕ patients (p=0 .13). #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @DrSinghvij |
| Suresh Balasubramanian @malignantheme @DrSinghvij #amyloidosisjc |
| Holly Lee @hollyleeYJ @a_staron @DrSinghvij @malignantheme Also, the MRD neg by one method might not be MRD neg by another: with next gen flow for MRD assessment, Kastritis et al. found that 5 out of 12 MRD➕ cases had very low residual tumor burden (<3x10^-5), which would have been undetected with lower sensitivity assays.#amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @vhugo8762 Me too! #amyloidosisJC |
| Dr. Jeffrey Zonder @Amyloid_Planet @NB191186 this is obviously not a typical cross-section of patients - perhaps a third of AL #amyloidosis patients are ASCT-eligible. #amyloidosisjc |
| Holly Lee @hollyleeYJ @a_staron @DrSinghvij @malignantheme With next gen flow, reported median sensitivity level was 2.3 x 10^−6 (range: 2 × 10^−6–3.1 × 10^-6). https://t.co/w2pgTPuXwr. #amyloidosisjc |
| Andrew Staron @a_staron @NB191186 @vhugo8762 We still need to better understand the clinical relevance of MRD for AL amyloidosis in my opinion. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme Some concluding points from this JC paper! 1. There may be value in bone marrow biopsy/ aspirate at end of therapy in AL amyloidosis patients who achieve VGPR/CR. MRD➕ is associated with 👎PFS in this group of patients. #amyloidosisjc @Amyloid_Planet @NB191186 @vsanchorawala |
| Suresh Balasubramanian @malignantheme Conclusion #2: MRD negativity is a robust surrogate endpoint for the design of clinical trials, and for optimizing individual patients’ treatment. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @a_staron @NB191186 @vhugo8762 I agree! See results of @a_staron from @BU_Amyloidosis at ISA 2020! #amyloidosisJC |
| Suresh Balasubramanian @malignantheme Conclusion #3: The sensitivity of the current standard assay for sFLC detection does not discern between MRD➕ vs MRD➖ among VGPR/CR patients. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @NB191186 presumably - suspect dara. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @holly_dlduwls struggled to understand this. thoughts? #amyloidosisjc |
| Andrew Staron @a_staron @holly_dlduwls @DrSinghvij @malignantheme The study we are discussing used MFC at minimum sensitivity 10^-4, which may be not sensitive enough in AL amyloidosis. According to detection levels reported by Kastritis et al. (https://t.co/sQI3rMQYGV) up to 42% of patients were MRD-positive at 10^-5 and 10^-6. #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @holly_dlduwls no statistical power with these numbers. But also, all these pts had excellent hematologic responses, whether they were MRD(-) or not. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @NB191186 Incorporating into clinical practice for AL amyloidosis only when in Hem CR, however, not changing or directing therapy based on results. #amyloidosisjc |
| Andrew Staron @a_staron RT @vsanchorawala: @NB191186 Incorporating into clinical practice for AL amyloidosis only when in Hem CR, however, not changing or directing therapy based on results. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @a_staron @holly_dlduwls @DrSinghvij @malignantheme minimum sensitvity of 10^-5 needed per IMWG consensus report in myeloma. #amyloidosisJC |
| Suresh Balasubramanian @malignantheme @NB191186 on the same note 🤔❓Currently no studies inform us how best to manage/ monitor patients in deep hematological response based on their MRD status. #amyloidosisjc |
| Holly Lee @hollyleeYJ @Amyloid_Planet @NB191186 Yes in their original 2017 study of total 173 patients, 38% underwent ASCT #amyloidosisjc. https://t.co/cqYraWYRlu. |
| Andrew Staron @a_staron @Amyloid_Planet @holly_dlduwls MRD-negative cohort with VGPR may have had a residual clonal PC population that wasn't detected by this particular technique at this sensitivity level. #amyloidosisjc |
| Vaishali Sanchorawala @vsanchorawala @NB191186 Not changing anything at this time if deep hemCR with MRD positive. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme To the group on closing remarks🤔❓How does MRD status guide frequency of follow up of patients after therapy? If a patient initially achieves MRD-CR but then progresses to MRD➕ CR on repeat follow up, does this indicate progression/ requirement for treatment? #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @NB191186 @DrSinghvij @SusanBal9 @malignantheme clarify? #amyloidosisjc |
| Victor H Jimenez-Zepeda @vhugo8762 MRD and mass spect are great tools to assess for AL amyloid and I agree there is lots to learn about them. Particularly, if there is potential to guide therapy or predict organ responses and survival outcomes #amyloidosisjc |
| Andrew Staron @a_staron @malignantheme Need to better understand how MRD status correlates with clinically important parameters/morbidity/organ response and OS in my opinion. Would not treat based on MRD-positivity alone otherwise. #amyloidosisJC |
| Dr. Jeffrey Zonder @Amyloid_Planet @malignantheme @NB191186 @vsanchorawala what we do not know is whether there is benefit to extension and/or switching therapy in pts who remain MRD(+) at the end of planned induction therapy for AL #amyloidosis in order to try and attain MRD (-) status. #amyloidosisjc thoughts anyone? |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet @NB191186 @DrSinghvij @SusanBal9 My belief is that though MRD negative by currently available modalities, they are not deep enough for a cure? #amyloidosisjc @Amyloid_Planet @NB191186 @holly_dlduwls @DrSinghvij |
| Vaishali Sanchorawala @vsanchorawala @BU_Amyloidosis |
| Dr. Jeffrey Zonder @Amyloid_Planet @vsanchorawala @a_staron @NB191186 @vhugo8762 @BU_Amyloidosis any hints? #amyloidosisjc |
| Dr. Jeffrey Zonder @Amyloid_Planet @vsanchorawala @NB191186 if not making any clinical decisions based on it, how are you incorporating it into clinical practice? #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet @NB191186 @vsanchorawala Definitely a good stimulus for considering MRD based clinical trials for extending treatment in AL amyloidosis as in MRD guided ALL clinical trials using blinatumumab #amyloidosisjc @Amyloid_Planet |
| Dr. Jeffrey Zonder @Amyloid_Planet @malignantheme it does not affect my usual frequency of clinical monitoring, nor would i change anything for shfit from MRD(-) to MRD(+) if usual clinical hematologic parameters remain unchanged #amyloidosisjc |
| Vijendra Singh @vijsinghmd @malignantheme @Amyloid_Planet @NB191186 @SusanBal9 @holly_dlduwls 2/2 MGUS course after MRD negativity. #amyloidosisjc @malignantheme |
| Vaishali Sanchorawala @vsanchorawala Great discussion #amyloidosisjc. Thank you. |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet Interesting report by Muchtar et al. 2019, looked at not only the depth of response (in this case nadir iFLC <2mg/dL) but also the impact of time to nadir iFLC on patient outcomes. #AmyloidosisJC @Amyloid_Planet |
| Dr. Jeffrey Zonder @Amyloid_Planet @malignantheme @NB191186 @vsanchorawala it would be interesting to see if maintenance improves PFS in MRD(+) pts, but need data to justify outside of a trial #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet Patients whose nadir iFLC occurred after 12 months from EOT had significantly longer PFS and OS compared to patients who reached nadir before 12 months. #amyloidosisjc (https://t.co/FKZ6ou7vwK) |
| Suresh Balasubramanian @malignantheme @Amyloid_Planet is there a role for MRD assessment not only at EOT but also, further out from EOT to inform patient outcomes? #amyloidosisjc @Amyloid_Planet |
| Holly Lee @hollyleeYJ @a_staron @NB191186 @vhugo8762 Yes, and also standardize the modality/sensitivity for MRD studies #amyloidosisjc |
| Victor H Jimenez-Zepeda @vhugo8762 Great discussion! Have a great night everyone! #amyloidosisjc @holly_diduwis |
| Andrew Staron @a_staron @Amyloid_Planet @vsanchorawala @NB191186 @vhugo8762 @BU_Amyloidosis Not all light chains are equally pathologic in my opinion; MRD may matter for a subset of patients. Data can have different interpretations. #amyloidosisjc |
| Suresh Balasubramanian @malignantheme @a_staron @Amyloid_Planet @vsanchorawala @NB191186 @vhugo8762 @BU_Amyloidosis can't agree more! #amyloidosisjc |
| Suresh Balasubramanian @malignantheme Thank you all for being part of this excellent thought provoking discussion on MRD in amyloidosis! Hope to see you all at ASH 2019 "Untangling Amyloidosis" Symposium on Dec 6 @ Orlando Convention Center @7AM. #amyloidosisjc Thank you @holly_dlduwls @NB191186 @Amyloid_Planet |
| Vijendra Singh @vijsinghmd RT @malignantheme: Thank you all for being part of this excellent thought provoking discussion on MRD in amyloidosis! Hope to see you all at ASH 2019 "Untangling Amyloidosis" Symposium on Dec 6 @ Orlando Convention Center @7AM. #amyloidosisjc Thank you @holly_dlduwls @NB191186 @Amyloid_Planet |
| Holly Lee @hollyleeYJ Thank you for the discussion everyone! #amyloidosisjc Thank you - @malignantheme @NB191186 @Amyloid_Planet |
| Dr. Jeffrey Zonder @Amyloid_Planet thanks all for interesting #amyloidosisjc discussion this evening. will post link to transcript soon @ https://t.co/myWHYQYT8p |
#amyloidosisJC content from Twitter.